back to the homepage
 
07:55–08:55
Cubex A1 + A2

Breakfast & INDUSTRY SYMPOSIUM

 
09:00–10:00
Cubex A1 + A2

PANEL DISCUSSION: How do we ensure treatments are available to everyone with IgAN?

Moderators: Heather Reich, Hernan Trimarchi

Panellists: Irene de Lourdes Noronha, Vivekanand Jha, Adrian Liew, Bonnie Schneider

 
10:00–11:00
Cubex A1 + A2

PLENARY SESSION 4: IgAN Pathogenesis 2

Chairs: Renato Monteiro, Xueqing Yu

Katherine Bull: Understanding the glomerular response to IgA deposition

Heather Reich: Immune cells in the kidney are they important in IgAN?

Dana Rizk: The role of complement in IgAN (the glomerulus and beyond)

 
11:00–11:30

Coffee break

 
11:30–11:50
Cubex A1 + A2

PLENARY SESSION 5: IIGANN Research Group Lecture 2

Chair: Mark Haas

Peter Boor: Pathomics and next generation pathology in IgAN and IgAVN

 
11:50–13:00
Cubex A1 + A2

FREE COMMUNICATIONS

Fabio Sallustio: Renal Progenitor Cells Can Modulate Inflammatory and Intestinal Immune Activation in IgA Nephropathy

Ying Zheng: CX3CR1+ monocytes/macrophages promote regional immune injury in mesangial proliferative glomerulonephritis through crosstalk with activated mesangial cells

Yuko Makita: Transglutaminase-2 specific IgA-producing plasma cells in experimental IgA nephropathy

Selvin Sundar Raj Mani: Gut Microbiome in IgA Nephropathy: Associations with Baseline Disease Presentation and Longitudinal Clinical Outcomes in South Asians

Yoshihito Nihei: Mucosal bacteria initiate production of anti-β2-spectrin IgA autoantibody through a mechanism of molecular mimicry

Francesca Zanoni: Polygenic Risk Score Predicts IgA Nephropathy Recurrence and Graft Failure in Kidney Transplant Recipients

Fabio Sallustio: MBL2 Deficiency and Graft Survival in Transplant Patients with IgA Nephropathy: Is Complement Inhibition Always Beneficial?

 
13:00–14:00
Cubex A1 + A2

Lunch & INDUSTRY SYMPOSIUM

 
14:00–15:00
Cubex A1 + A2

PLENARY SESSION 6: Treatment 1

Chairs: Daniel Cattran, Vladimir Tesar

Jürgen Floege: What do the KDIGO Guidelines NOT tell us?

Richard Lafayette: Who should we treat?

Sydney Chi Wai Tang: How best to manage CKD in IgAN?

 
15:00–15:30
Cubex A1 + A2

FREE COMMUNICATIONS

Linlin Xu: Unveiling Genetic Determinants of Steroid Responsiveness in IgA Nephropathy: A TESTING Cohort Study

David L. Hölscher: Pathomics-based estimation of treatment effects for corticosteroids in IgAN

Xujie Zhou: Genome-wide association study meta-analysis reveals 50 susceptibility loci for IgA nephropathy and identifies B-cell receptor signaling to NF-κB pathway as a potential therapeutic target

 
15:30–16:00

Coffee break

 
16:00–17:00
Cubex A3

MODERATED POSTER SESSION

Moderator: Kerstin Ebefors

Meijun Si: Revealing the Spatial Structure of IgA Immune Complexes in IgA Nephropathy Using Volume Electron Microscopy

Stacy D. Hall: Complement C3: A necessary component of pathogenic IgA1-containing immune complexes in IgA nephropathy

Zhenhai Zhang: Functional characterization of a novel anti-Gd-IgA1 autoantibody P4 in IgA nephropathy pathogenesis

Tibor Schomber: Effects of anti-APRIL antibody treatment versus dual APRIL/BAFF inhibition and anti-BAFF antibody treatment in wild type mice

Jan Novak: In vivo evidence that mesangioproliferative activity of IgA1-IgG immune complexes in IgA nephropathy requires complement C3 and can be prevented by a protein tyrosine kinase inhibitor

Colin Reily: NF-kB inhibitor increases production of galactose-deficient IgA1 and modulates activation of multiple transcription factors in several subpopulations of EBV-immortalized B cells from IgAN patients and healthy controls

Chee Kay Cheung: Urinary biomarker analysis reveals rapid intrarenal anti-inflammatory and anti-fibrotic effects of sparsentan in IgA nephropathy in the SPARTAN study

Kirk J. Rowley: Targeting APRIL and BAFF pathways: Divergent effects on immune populations and protective immunity, with implications for IgAN management

Jicheng Lv: PEGylated Clostridium ramosum IgA protease clears both circulating and deposited IgA1 as a potential disease-modifying therapy for IgA nephropathy

Kazuaki Mori: Sparsentan decreases mesangial IgA deposition in gddY mice; a possible role for mesangial-cell- surface autoantigen expression


Moderator: Yuko Makita

Alexandra Audemard-Verger: Recommendations on diagnosis and treatment of adult-onset IgA Vasculitis proposed by the European IgA Vasculitis Study Group: focus on kidney involvement

Zhiqiang Du: Preclinical and phase I clinical study of RG002C0106: a GalNAc-siRNA conjugate for complement-related glomerular diseases

Federica Papadia: Epidemiological and Prognostic Insights into IgA Nephropathy: A Regional Cohort Study from Southern Italy

Selvin Sundar Raj Mani: Baseline and Longitudinal Associations between serum C3/C4 levels and tissue complement biomarkers and IgA Nephropathy in South Asia

Nobuo Tsuboi: Prognostic Significance of Persistent Hematuria in Japanese Patients with IgA Nephropathy: Findings from the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS)

Hiroyuki Ueda: Prognostic impact of proteinuria recurrence in IgA nephropathy: A post hoc analysis of the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS)

Shinya Yokote: Prognosis of Elderly Patients with IgA Nephropathy: A Post Hoc Analysis of the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS)

Dita Maixnerova: Intercontinental survey of patients with IgA nephropathy – preliminary analysis

Keiichi Matsuzaki: Clinical Remission in IgA Nephropathy : Visualization of transition patterns and identification of an appropriate time point for prognostic assessment

Eyal Rahmani: Long-Term Outcomes in IgA Nephropathy: Findings from the ERKNet Patient Registry (ERKReg)


Moderator: Matthew B. Renfrow

Xujie Zhou: Causal Relationships Between Gut Microbiota and IgA Nephropathy: Evidence from Mendelian Randomization and Microbiome Validation

Benedetta De Ponte Conti: Investigation of gut-derived immune cell in IgA nephropathy

Fengtao Cai: Proteomics Unveils Molecular Profiles and Potential Pathogenic Mechanisms in IgA Nephropathy

Jacqueline Haller: Association of Urinary Inflammatory Biomarkers with Disease Activity and Progression Risk in IgAN and IgAVN: Findings from a Single-Center Cohort

Hannes Olauson: Renal and circulating Klotho levels in patients with IgA nephropathy

Joshua Strzalka: Soluble Fcγ receptor ectodomains as inhibitors of FcγR activation in immune complex-mediated diseases

Karin Bergen: Lower urine epidermal growth factor to monocyte chemoattractant protein 1 ratio is associated with elevated biomarkers of endothelial dysfunction in IgA nephropathy

Jangwook Lee: Age- and Sex-Specific Gut Microbiome Alterations in IgA Nephropathy: Implications for Disease Pathogenesis and Progression

Karin Bergen: Plasma endothelial biomarkers in relation to albuminuria, kidney function and CKD progression in IgA-nephropathy (encore from 62nd ERA congress)

Yudai Tsuji: Comparative proteomic analysis of glomeruli and circulating IgA-immune complexes in IgA nephropathy


Moderator: Xu-jie Zhou

Shu Qu: Genetic regulation and therapeutic targeting of MTMR3 reshape TLR9-mediated IgA responses

Sho Hamaguchi: Deep shotgun metagenomic analysis of the oral microbiome identifies extrachromosomal mobile genetic elements associated with IgA nephropathy

Cheng-Hsu Chen: The Genetic Study Identifies Susceptibility Loci for IgA Nephropathy

Francesca Annese: Molecular endophenotyping of IgA Nephropathy patients reveals immune-driven subgroups with distinct clinical outcomes

Amandine Badie: The role of sCD89 myeloid receptor in glomerular hypercellularity in childhood IgA nephropathy

Ming Li: The effects of multi-locus interaction on IgA nephropathy in Han Chinese population

Filippo Azzali: Engineering of IgA-specific CARs for CAR-T cell therapy against IgA nephropathy

Connor Hebborn: Evaluation of inhibitory oligotherapy for modulation of IgA expression

Mayuko Kawabe: Tonsillar Immune Signatures in IgA Nephropathy: Elevated KLRG1 and ZBTB16 Expression in Germinal Center Regions

Kerstin Ebefors: Activation of mesangial cells via phagocytosis in IgA nephropathy

 
18:00–22:00

Conference Dinner

 

Last update on 27 August 2025.

The programme might be subject to necessary changes.

© 2024–2025 GUARANT International spol. s r. o.